Headquartered in Paasheuvelweg 25, Amsterdam Fiscal year ends December NASDAQ: QURE uniqure.com
uniQure N.V. is a gene therapy company focused on developing single-administration treatments with potentially curative results for patients with severe medical conditions. The company has achieved regulatory approval for its gene therapy for hemophilia B (marketed as HEMGENIX through a partnership with CSL Behring) and is advancing a proprietary pipeline of gene therapies targeting Huntington's disease (AMT-130), refractory mesial temporal lobe epilepsy (AMT-260), Fabry disease (AMT-191), and other severe diseases. uniQure trades on NASDAQ under the ticker QURE and operates from locations in Lexington, Massachusetts and Amsterdam, the Netherlands. Updated
uniQure lost more than a third of its value in a single session after Huntington's data spooked investors, but Wall Street's price target still points to triple-digit upside. Whether that gap represents…
Wall Street analysts reshuffled their bets on Thursday as geopolitical fires, a Fed dissent surprise, and a brutal semiconductor selloff forced some major rating reversals across insurance, gaming, tech, and energy stocks.
Wall Street is turning constructive on three clinical-stage biotechs simultaneously, each sitting at the edge of a binary catalyst. The analyst calls on uniQure (NASDAQ:QURE), Syndax Pharmaceuticals (NASDAQ:SNDX), and Erasca (NASDAQ:ERAS) share…
Pre-Market Stock Futures: Futures are down big as oil shoots higher on Tuesday. After a big early morning sell-off on Monday, the buy-the-dip buyers returned with a vengeance, and by the end…
Tuesday's top analyst upgrades and downgrades included Ally Financial, Apple, Ardelyx, Block, DocuSign, D.R. Horton, Enovix, EOG Resources, Ford, Futu, Micron Technology, Novavax, PayPal, Pfizer and TG Therapeutics.
Thursday's top analyst upgrades and downgrades included Adobe, American Airlines, Coupa Software, Delta Air Lines, Host Hotels & Resorts, Nio, Novo Nordisk, Ralph Lauren, Roblox, SentinelOne and Walt Disney.
Alliance Data, Cimarex Energy, Myriad Genetics and Nestle were among Tuesday afternoon's analyst upgrades and downgrades.
Friday's top analyst upgrades and downgrades included AT&T, Cisco Systems, Datadog, Dish Network, Energy Transfer, Pioneer Natural Resources, Splunk and Virgin Galactic.
Thursday's top analyst upgrades and downgrades included Carnival, Dow, Goldman Sachs, Micron Technology, Netflix, Oracle, Snap, Spotify and Twitter.
A new Stifel research report includes the firm's biotech stock picks for 2021. These five have the biggest upside to the posted price targets and are best suited for patient, aggressive growth…
Health care has been a top performer this year, and there is every reason to believe that performance will carry through into 2021. These are four of the highest-ranked health care ideas…
Tuesday's top analyst upgrades, downgrades and initiations included Alphabet, Amazon.com, Beyond Meat, CommScope, Enphase Energy, Nabors Industries, Netflix, Nike, Roku, Tesla, Uber Technologies and Williams Companies.
Here are eight secondary offerings that have been filed with a grand tally of about $3 billion combined.
uniQure N.V. is a gene therapy company focused on developing single-administration treatments with potentially curative results for patients with severe medical conditions.
The Wall Street consensus 12-month price target for QURE is $62.51.
